Lanreotide Autogel ® in the Management of Acromegaly

ISSN： 0012-6667

Source： Drugs, Vol.68, Iss.5, 2008-01, pp. : 724-724

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Lanreotide Autogel®: A Review of its Use in the Management of Acromegaly

By Croxtall Jamie D. Scott Lesley J.

Drugs, Vol. 68, Iss. 5, 2008-01 ,pp. : 711-723

Adis International

Access to resources Recommend Favorite

Population Pharmacokinetic Analysis of Lanreotide Autogel® in Healthy Subjects: Evidence for Injection Interval of Up to 2 Months

By Trocóniz Iñaki F.

Clinical Pharmacokinetics, Vol. 48, Iss. 1, 2009-01 ,pp. : 51-62

Adis International

Access to resources Recommend Favorite

Guidelines for the management of acromegaly

Inpharma, Vol. 1, Iss. 1361, 2002-01 ,pp. : 2-2

Adis International

Access to resources Recommend Favorite

Current management of acromegaly

By Díez J.J. Iglesias P.

Expert Opinion on Pharmacotherapy, Vol. 1, Iss. 5, 2000-07 ,pp. : 991-1006

Informa Healthcare

Access to resources Recommend Favorite

The place of pegvisomant in the management of acromegaly

By Parkinson Craig Trainer Peter J

Expert Opinion on Investigational Drugs, Vol. 10, Iss. 9, 2001-09 ,pp. : 1725-1735

Informa Healthcare

Access to resources Recommend Favorite